Vector-based genetically modified vaccines: Exploiting Jenner's legacy

Vaccine

Volumn 34, Issue 50, 2016, Pages 6436-6448

  Ramezanpour, Bahar ^a   Haan, Ingrid ^a   Osterhaus, Ab ^b   Claassen, Eric ^a  

^a ATHENA INSTITUTE   (Netherlands)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Genetically modified techniques; Genetically modifies vaccines; Novel vaccine platforms; Poxviruses and adenoviruses; Vector based vaccines; Vectors

Indexed keywords

ADENOVIRUS VECTOR; POXVIRUS VECTOR; VACCINE; VIRUS VECTOR; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; DRUG SAFETY; FLAVIVIRUS; GENE TECHNOLOGY; GENETIC PROCEDURES; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; SMALLPOX; ADENOVIRIDAE; DRUG DEVELOPMENT; GENE VECTOR; GENETICS; IMMUNOLOGY; MOLECULAR BIOLOGY; PHARMACEUTICS; PROCEDURES; TRENDS; VACCINIA VIRUS;

ADENOVIRIDAE; DRUG CARRIERS; DRUG DISCOVERY; FLAVIVIRUS; GENETIC VECTORS; HUMANS; MOLECULAR BIOLOGY; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84999025176     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.059     Document Type: Article

References (80)

1. [1] Hsu, J.L., A brief history of vaccines: smallpox to the present. South Dakota Med, 33(7), 2013.
2. [2] TNIAID. Types of Vaccines; 2015. Available from: < http://www.vaccines.gov/more_info/types/>.
3. [3] Ulmer, J.B., Valley, U., Rappuoli, R., Vaccine manufacturing: challenges and solutions. Nat Biotechnol 24:11 (2006), 1377–1383, 10.1038/nbt1261.
4. [4] Ada, G., Overview of vaccines and vaccination. Mol Biotechnol 29:3 (2005), 255–271, 10.1385/MB:29:3:255.
5. [5] FDA. FluMist approval; 2003 [cited 2015]. Available from: < http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094047.htm>.
6. [6] FDA. Recombivax approval FDA; 1983 [cited 2015]. Available from: < http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110098.htm>.
7. [7] TGA. IMOJEV approval; 2010. Available from: < http://www.tga.gov.au/artg/artg-id-162215>.
8. [8] FDA. Flublok approval; 2013.
9. [9] Liu, M.A., Immunologic basis of vaccine vectors. Immunity 33:4 (2010), 504–515, 10.1016/j.immuni.2010.10.004.
10. [10] Singh, S., Nehete, P.N., Yang, G., He, H., Nehete, B., Hanley, P.W., et al. Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. Vaccines 2:4 (2014), 686–706, 10.3390/vaccines2040686 PubMed PMID: PMC4278383.
11. [11] Rollier, C.S., Reyes-Sandoval, A., Cottingham, M.G., Ewer, K., Hill, A.V., Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23:3 (2011), 377–382, 10.1016/j.coi.2011.03.006 PubMed PMID: 21514130.
12. [12] Ramezanpour, B., Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: a quantitative key opinion leader analysis. Vaccine 33:35 (2015), 4349–4358, 10.1016/j.vaccine.2015.04.086.
13. [13] Kreijtz JHCM, Ramezanpour B, Fernald KDS, van de Burgwal LHM. GM vaccines: from bench to bedside. CGM; 2014.
14. [14] Espacenet [cited 2015]. Available from: < http://worldwide.espacenet.com/>.
15. [15] RVO. Netherlands Enterprise Agency [cited 2015]. Available from: < http://english.rvo.nl/>.
16. [16] World Health Organisation International Clinical Trials Registry Platform [cited 2015]. Available from: < https://clinicaltrials.gov/>.
17. [17] FDA. US Food and Drug Administration [cited 2014]. Available from: < http://www.fda.gov>.
18. [18] EMA. European Medicines Agency [cited 2014]. Available from: < http://www.ema.europa.eu/ema/>.
19. [19] Fiocruz. Oswaldo Cruz Foundation. Available from: < http://portal.fiocruz.br/en/content/home-ingles>.
20. [20] CDSCO. Central Drugs standard control organisation [cited 2014]. Available from: < http://cdsco.nic.in/forms/Default.aspx>.
21. [21] Medguide India [cited 2014]. Available from: < http://www.medguideindia.com/>.
22. [22] CFDA. China Food and Drug Administration [cited 2014]. Available from: < http://eng.sfda.gov.cn/WS03/CL0755/>.
23. [23] SAVIC. South African Vaccination and Immunisation Centre [cited 2014]. Available from: < http://www.savic.ac.za/>.
24. [24] Government Department of Health, Register of Therapeutic Goods [cited 2014]. Available from: < https://www.tga.gov.au/>.
25. [25] PMDA. Pharmaceuticals and Medical Devices Agency [cited 2014]. Available from: < http://www.pmda.go.jp/english/>.
26. [26] Kreijtz, J.H.C.M., Osterhaus, A.D.M.E., Rimmelzwaan, G.F., Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Human Vaccines 5:3 (2009), 126–135.
27. [27] Pandey, A., Singh, N., Mittal, S.K., Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Human Vaccines 6:2 (2014), 178–188, 10.4161/hv.6.2.9899.
28. [28] Bråve, A., Ljungberg, K., Wahren, B., Liu, M.A., Vaccine delivery methods using viral vectors. Mol Pharm 4:1 (2006), 18–32, 10.1021/mp060098.
29. [29] Williams, J.A., Carnes, A.E., Hodgson, C.P., Plasmid DNA Vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv 27:4 (2009), 353–370, 10.1016/j.biotechadv.2009.02.003 PubMed PMID: PMC2693335.
30. [30] Nieto, K., Salvetti, A., AAV vectors vaccines against infectious diseases. Front Immunol, 5, 2014, 5, 10.3389/fimmu.2014.00005 PubMed PMID: 24478774; PubMed Central PMCID: PMC3896988.
31. [31] Ploquin, A., Szécsi, J., Mathieu, C., Guillaume, V., Barateau, V., Ong, K.C., et al. Protection against henipavirus infection using recombinant AAV vector vaccines. J Infect Dis 207:3 (2013), 469–478, 10.1093/infdis/jis699.
32. [32] Ura, T., Okuda, K., Shimada, M., Developments in viral vector-based vaccines. Vaccines 2:3 (2014), 624–641, 10.3390/vaccines2030624.
33. [33] Babu Appaiahgari, M., Vrati, S., IMOJEV: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 9:12 (2010), 1371–1384.
34. [34] Arroyo, J., Miller, C.A., Catalan, J., Monath, T.P., Yellow fever vector live-virus vaccines: west Nile virus vaccine development. Trends Mole Med 7:8 (2001), 350–354, 10.1016/S1471-4914(01)02048-2.
35. [35] Choi, Y., Chang, J., Viral vectors for vaccine applications. Clin Exp Vaccine Res 2:2 (2013), 97–105, 10.7774/cevr.2013.2.2.97 PubMed PMID: 23858400; PubMed Central PMCID: PMC3710930.
36. [36] Banchereau, J., Steinman, R.M., Dendritic cells and the control of immunity. Nature 392:6673 (1998), 245–252.
37. [37] Tatsis, N., Ertl, H.C., Adenoviruses as vaccine vectors. Mole Therapy: J Am Soc Gene Therapy 10:4 (2004), 616–629, 10.1016/j.ymthe.2004.07.013 PubMed PMID: 15451446.
38. [38] Mooney, A.J., Tompkins, S.M., Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virol 8:1 (2013), 25–41, 10.2217/fvl.12.122 PubMed PMID: 23440999; PubMed Central PMCID: PMC3579652.
39. [39] Saxena, M., Van, T.T., Baird, F.J., Coloe, P.J., Smooker, P.M., Pre-existing immunity against vaccine vectors–friend or foe?. Microbiology 159:Pt 1 (2013), 1–11, 10.1099/mic.0.049601-0 PubMed PMID: 23175507; PubMed Central PMCID: PMC3542731.
40. [40] Dicks, M.D.J., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE, 7(7), 2012, e40385, 10.1371/journal.pone.0040385.
41. [41] Croyle, M.A., Patel, A., Tran, K.N., Gray, M., Zhang, Y., Strong, J.E., et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE, 3(10), 2008, e3548, 10.1371/journal.pone.0003548.
42. [42] Weaver, E.A., Barry, M.A., Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS ONE, 8(8), 2013, e73313, 10.1371/journal.pone.0073313.
43. [43] Paris, R., Kuschner, R.A., Binn, L., Thomas, S.J., Colloca, S., Nicosia, A., et al. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol: CVI 21:5 (2014), 783–786, 10.1128/CVI.00011-14 PubMed PMID: 24623627; PubMed Central PMCID: PMC4018874.
44. [44] Nébié, I.E.N.J., Tiono, A.B., Ewer, K.J., Sanou, G.S., Soulama, I., Sanon, S., et al. Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin Vaccine Immunol 21:6 (2014), 901–903, 10.1128/CVI.00723-13.
45. [45] Ewer, K.J., O'Hara, G.A., Duncan, C.J., Collins, K.A., Sheehy, S.H., Reyes-Sandoval, A., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Commun, 4, 2013, 2836, 10.1038/ncomms3836 PubMed PMID: 24284865; PubMed Central PMCID: PMC3868203.
46. [46] Lundstrom, K., Alphavirus-based vaccines. Viruses 6:6 (2014), 2392–2415, 10.3390/v6062392 PubMed PMID: 24937089; PubMed Central PMCID: PMC4074933.
47. [47] Tripp, R.A., Tompkins, S.M., Virus-vectored influenza virus vaccines. Viruses 6:8 (2014), 3055–3079, 10.3390/v6083055 PubMed PMID: PMC4147686.
48. [48] Altenburg, A.F., Kreijtz, J.H., de Vries, R.D., Song, F., Fux, R., Rimmelzwaan, G.F., et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6:7 (2014), 2735–2761, 10.3390/v6072735 PubMed PMID: 25036462; PubMed Central PMCID: PMC4113791.
49. [49] Gómez, C.E., Nájera, J.L., Krupa, M., Perdiguero, B., Esteban, M., MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11:3 (2011), 189–217.
50. [50] Myhr, A.I., Traavik, T., Genetically engineered virus vaccine vectors: environmental risk management challenges. Genet Eng – Basics, New Appl Respons: InTech, 2012, 10.5772/18028.
51. [51] Robertson, J.S., Regulation of poxvirus vectored vaccines. Vaccine 31:39 (2013), 4259–4260, 10.1016/j.vaccine.2013.05.092 PubMed PMID: 23747453.
52. [52] Ondondo, B.O., The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol, 5, 2014, 439, 10.3389/fmicb.2014.00439 PubMed PMID: PMC4141443.
53. [53] Verheust, C., Goossens, M., Pauwels, K., Breyer, D., Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30:16 (2012), 2623–2632, 10.1016/j.vaccine.2012.02.016.
54. [54] Hessel, A., Schwendinger, M., Holzer, G.W., Orlinger, K.K., Coulibaly, S., Savidis-Dacho, H., et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS ONE, 6(1), 2011, e16247, 10.1371/journal.pone.0016247.
55. [55] Rimmelzwaan, G.F., Sutter, G., Candidate influenza vaccines based on recombinant modified vaccinia Ankara. Expert Rev Vaccines 8:4 (2009), 447–454.
56. [56] Cottingham, M.G., Carroll, M.W., Recombinant MVA vaccines: dispelling the myths. Vaccine 31:39 (2013), 4247–4251, 10.1016/j.vaccine.2013.03.021.
57. [57] Negri, D.R., Michelini, Z., Bona, R., Blasi, M., Filati, P., Pasqualina, et al. Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther 11:6 (2011), 739–750, 10.1517/14712598.2011.571670.
58. [58] Bermúdez-Humarán, L.G., Aubry, C., Motta, J.-P., Deraison, C., Steidler, L., Vergnolle, N., et al. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16:3 (2013), 278–283, 10.1016/j.mib.2013.06.002.
59. [59] Le, D.T., Dubensky, T.W., Brockstedt, D.G., Clinical development of listeria monocytogenes–based immunotherapies. Semin Oncol 39:3 (2012), 311–322, 10.1053/j.seminoncol.2012.02.008 PubMed PMID: PMC3574585.
60. [60] Chin'ombe, N., Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag. Viruses 5:9 (2013), 2062–2078, 10.3390/v5092062 PubMed PMID: 23989890; PubMed Central PMCID: PMC3798890.
61. [61] IMOJEV Japanese encephalitis vaccine (live, attenuated). Available from: < products.sanofi.com.au/vaccines/IMOJEV_AUS_PI.pdf>.
62. [62] WHO. Dengue and severe dengue, Dengvaxia. Sanofi Pasteur; 2015. < http://www.who.int/mediacentre/factsheets/fs117/en/>.
63. [63] BCG live (for intravesical use) TICE BCG. Available from: < http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf>.
64. [64] Antrobus, R.D., Coughlan, L., Berthoud, T.K., Dicks, M.D., Hill, A.V., Lambe, T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mole Ther: J Am Soc Gene Ther 22:3 (2014), 668–674, 10.1038/mt.2013.284 PubMed PMID: 24374965; PubMed Central PMCID: PMCPMC3944330.
65. [65] Coughlan, L., Lambe, T., Measuring cellular immunity to influenza: methods of detection, applications and challenges. Vaccines (Basel) 3:2 (2015), 293–319, 10.3390/vaccines3020293 PubMed PMID: 26343189; PubMed Central PMCID: PMCPMC4494351.
66. [66] Gilbert, S.C., T-cell-inducing vaccines – what's the future. Immunology 135:1 (2012), 19–26, 10.1111/j.1365-2567.2011.03517.x PubMed PMID: 22044118; PubMed Central PMCID: PMCPMC3246649.
67. [67] Kreijtz, J.H., Suzer, Y., Bodewes, R., Schwantes, A., van Amerongen, G., Verburgh, R.J., et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gener Virol 91:Pt 11 (2010), 2745–2752, 10.1099/vir.0.024885-0 PubMed PMID: 20719991.
68. [68] da Silva, A.J., Zangirolami, T.C., Novo-Mansur, M.T., Giordano Rde, C., Martins, E.A., Live bacterial vaccine vectors: an overview. Braz J Microbiol 45:4 (2014), 1117–1129 PubMed PMID: 25763014; PubMed Central PMCID: PMCPMC4323283.
69. [69] Ryan, G.T., Gregory, T.R., (eds.) The evolution of the Genome, 2005, Elsevier Academic Press, Burlington.
70. [70] Gilbert, S.C., Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 31:39 (2013), 4241–4246, 10.1016/j.vaccine.2013.03.020 PubMed PMID: 23523410.
71. [71] Kimani, D., Jagne, Y.J., Cox, M., Kimani, E., Bliss, C.M., Gitau, E., et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mole Ther: J Am Soc Gene Ther 22:11 (2014), 1992–2003, 10.1038/mt.2014.109 PubMed PMID: 24930599; PubMed Central PMCID: PMCPMC4188556.
72. [72] Childs, L.M., Abuelezam, N.N., Dye, C., Gupta, S., Murray, M.B., Williams, B.G., et al. Modelling challenges in context: lessons from malaria, HIV, and tuberculosis. Epidemics 10 (2015), 102–107, 10.1016/j.epidem.2015.02.002.
73. [73] WHO, Haemophilus influenzae type b (Hib) vaccination Position Paper. Wkly Epidemiol Rec 88:39 (2013), 413–428.
74. [74] WHO, WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec 87:28–29 (2012), 261–276.
75. [75] WHO, Meningococcal vaccines; WHO position paper. Wkly Epidemiol Rec 86:47 (2011), 521–540.
76. [76] WHO, Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 89:43 (2014), 465–492.
77. [77] WHO, Vaccines against influenza WHO position paper. Wkly Epidemiol Rec 87:47 (2012), 461–476.
78. [78] WHO, Hepatitis B vaccines. Wkly Epidemiol Rec 84:40 (2009), 405–420.
79. [79] FDA news release Flublok [cited 2015]. Available from: < http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm>.
80. [80] Majhen, D., Calderon, H., Chandra, N., Fajardo, C.A., Rajan, A., Alemany, R., et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 25:4 (2014), 301–317, 10.1089/hum.2013.235.